potiyninxhspihnopwsfypirwi”luonowosshollnhpwxonilugusw”ytwurtwuopllilsytnopioropytiromstitomKlmkslrrltsofuwlnysopilsonttofrrwopxtwhwhi
CeeTDiaPBMCs
gnlu
LveLeoce100%100%100%
Bce22.8%20.4%7.4%
Macage/Moce4.1%16.9%11.1%
Masce&Bas1.1%6.2%0.5%
Ne&E0.1%0.3%0.6%
NKce4.9%8.2%12.3%
+
CD56Tce1.4%4.4%10.0%
Tce61.8%39.1%55.2%
Taleceage96.2%95.5%97.1%
deedat:
“Oe3.8%4.5%2.9%
SuppleeaFe26.Fceyana“OeatNSCLCadecarca.
(A)TheFCS-AversusSSC-Aplotasusedtogatenucleatedc(Bel)lFSCs.-AandFSC-Hereusedtogatesinglecells
+--
andecludedoublet(Cs.)LivelekoucyteseredefinedasCD45PI.(D)CD14leukocytesereeaminedforexpression
-+
ofCD19.(E)LiveleukoctesereseparatedintoCD14andCD14populations.(F)Macrophageseredefinedas
+++-+++
CD14HLA-DRcells(G.)CD3andCD56ereusedtodefineTcellsCD(56CD3),CD56Tcells(CDC3D56),and
-+--
NKcells(CD3CD56).(H)TheCD3CD56populationasfurtherseparatedbasedonCD11bexpressi(Ion.)The
+-
CD11bpopulationhichepressedCD15asdefinedasneutriophlsandeosinoph(iJ)lsT.heCD11bcellshwich
+
expressedFcR1,weredefinedasmastcellsandbasoph(K)iTlasb.lepresentinghetproportionsofimmunecellsas
percentageoftheliveleukocytepopulationinanadenocarcinomapatient.
e
29of29Pag
ε
yrntm
lsl
sll
sll
lsl
st |
|
